HCAT Stock Forecast & Price Target

Health Catalyst is viewed favorably because Project Nexus is reshaping the business into a simpler, more efficient operating model with roughly $30M in annualized savings, including quarterly OpEx declines of $3M to $4M and COGS declines of $1M to $2M, which should help protect EBITDA even as revenue normalizes. The company’s core technology platform still appears strategically important to large health systems, and the emphasis on the intelligence and application layers, supported by AI/Ignite capabilities and a refreshed leadership team, strengthens the long-term value proposition by aligning the product set more closely with customer demand for performance improvement and cost management. Although FY26 revenue is now estimated at $262.5M and FY27 at $220.8M amid DOS-to-Ignite migration and retention pressure, the outlook remains constructive because the expected profitability improvement, mid-60% adjusted tech gross margins near term, and potential recovery in FY27 suggest the business can emerge leaner and better positioned for renewed growth.

Health Catalyst is facing a difficult transformation after the Vitalware divestiture, which removed a meaningful earnings contributor and exposed the fragility of the go-forward model, as shown by Vitalware’s ~$37 million of 2025 revenue and $11.4 million of 1H'26 adj-EBITDA contribution against FY'26 guidance that fell 5.7% at the midpoint for revenue and 42.1% for adj-EBITDA. The company still has to navigate churn and down-sell risk among DOS clients, a pressured healthcare end market, and a highly competitive landscape where homegrown solutions, major cloud and enterprise vendors, EHR companies, and consultancies all compete for budget-constrained customers. In addition, the shift toward lower-margin tech-enabled managed services, whose margins start near 0% adj-GPM and are expected only to mature into the mid-20% range versus the historical mid-30% professional services business, creates execution risk at a time when management itself expects a substantial 2H'26 step-down in revenue and adj-EBITDA.